These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22336987)

  • 1. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms.
    Shavit L; Lifschitz MD; Epstein M
    Kidney Int; 2012 May; 81(10):955-968. PubMed ID: 22336987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
    Epstein M; Kovesdy CP; Clase CM; Sood MM; Pecoits-Filho R
    Am J Kidney Dis; 2022 Nov; 80(5):658-666. PubMed ID: 36057467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
    Epstein M
    Am J Med; 2006 Nov; 119(11):912-9. PubMed ID: 17071154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mineralocorticoid receptor antagonists in chronic kidney disease - pros and cons].
    Jędras M; Filipowicz E
    Wiad Lek; 2017; 70(6 pt 2):1205-1208. PubMed ID: 29533915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid Receptor Blockade in End-Stage Renal Disease.
    Lyubarova R; Gosmanova EO
    Curr Hypertens Rep; 2017 May; 19(5):40. PubMed ID: 28451852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure.
    Allen LA; Shetterly SM; Peterson PN; Gurwitz JH; Smith DH; Brand DW; Fairclough DL; Rumsfeld JS; Masoudi FA; Magid DJ
    Circ Heart Fail; 2014 Jan; 7(1):43-50. PubMed ID: 24281136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure.
    Cooper LB; Hammill BG; Peterson ED; Pitt B; Maciejewski ML; Curtis LH; Hernandez AF
    Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28073850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety.
    Bomback AS
    Blood Purif; 2016; 41(1-3):166-70. PubMed ID: 26765793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J; Caballero R; Delpón E
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study.
    Whittaker A; Kragh ÅM; Hartleib-Geschwindner J; Albayaty M; Backlund A; Greasley PJ; Heijer M; Kjaer M; Forte P; Unwin R; Wernevik L; Ericsson H
    Clin Transl Sci; 2020 Mar; 13(2):275-283. PubMed ID: 31584739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.
    Buysse JM; Huang IZ; Pitt B
    Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists.
    Suthar SD; Middleton JP
    Semin Dial; 2016; 29(1):52-61. PubMed ID: 26242304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone blockade in CKD: emphasis on pharmacology.
    Schwenk MH; Hirsch JS; Bomback AS
    Adv Chronic Kidney Dis; 2015 Mar; 22(2):123-32. PubMed ID: 25704349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.
    Davel AP; Jaffe IZ; Tostes RC; Jaisser F; Belin de Chantemèle EJ
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H989-H999. PubMed ID: 29957022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.
    Charytan DM; Himmelfarb J; Ikizler TA; Raj DS; Hsu JY; Landis JR; Anderson AH; Hung AM; Mehrotra R; Sharma S; Weiner DE; Williams M; DiCarli M; Skali H; Kimmel PL; Kliger AS; Dember LM;
    Kidney Int; 2019 Apr; 95(4):973-982. PubMed ID: 30473139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.
    Trevisan M; de Deco P; Xu H; Evans M; Lindholm B; Bellocco R; Barany P; Jernberg T; Lund LH; Carrero JJ
    Eur J Heart Fail; 2018 Aug; 20(8):1217-1226. PubMed ID: 29667759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone-receptor antagonism and end-stage renal disease.
    McLaughlin N; Gehr TW; Sica DA
    Curr Hypertens Rep; 2004 Aug; 6(4):327-30. PubMed ID: 15257869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis.
    Chen KT; Kang YN; Lin YC; Tsai IL; Chang WC; Fang TC; Wu MS; Kao CC
    Clin J Am Soc Nephrol; 2021 Jun; 16(6):916-925. PubMed ID: 34117083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.